Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 2:51 AM ET


Company Overview of Tokai Pharmaceuticals, Inc.

Company Overview

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate, galeterone, is a multi-targeted, oral small molecule being developed for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. The company was founded in 2004 and is based in ...

255 State Street

6th Floor

Boston, MA 02109

United States

Founded in 2004

17 Employees



Key Executives for Tokai Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 40
Total Annual Compensation: $608.5K
Chief Financial Officer
Age: 34
Total Annual Compensation: $201.7K
Chief Medical Officer and Head of Research & Development
Age: 57
Total Annual Compensation: $408.8K
Compensation as of Fiscal Year 2014.

Tokai Pharmaceuticals, Inc. Key Developments

Tokai Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 12:40 PM

Tokai Pharmaceuticals, Inc. Presents at Jefferies Autumn 2015 Global Healthcare Conference, Nov-19-2015 12:40 PM. Venue: The May Fair Hotel, Stratton Street, London, United Kingdom.

Tokai Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 03:00 PM

Tokai Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 03:00 PM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Jodie Pope Morrison, Chief Executive Officer, President and Director.

Tokai Seeks Acquisition

Tokai Pharmaceuticals, Inc. (NasdaqGM:TKAI) intend to use the net proceeds from the sale of securities for general corporate purposes. General corporate purposes may include the research, development and commercialization of products arising out of our product development pipeline, acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.

Similar Private Companies By Industry

Company Name Region
Mercator MedSystems, Inc. United States
NanoInjection Technologies, LLC United States
PSMA Development Company L.L.C. United States
Serina Therapeutics, Inc. United States
Twentyfirst Century Biochemicals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tokai Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at